Rebus Holdings Inc (RBSH)

[Mrragu]

Note from 10-Q... BACK IN BUSINESS

During February of 2018, we curtailed our operations due to our lack of cash, but upon the cancellation of the Ridgeway license, we are resuming preclinical development.

Back in clinical development of drug platforms. "We have recently began working on developing IND (investigational new drug) approved studies for our adenosine receptor technology platform"

Going all in on RT-AR001 A novel immuno-oncology delivery technology targeting adenosine receptor antagonists for the treatment of cancer!

Didn't take long for Colin to grab the ball and take off with it. The 8-K 10/08 changed the entire scope of Inspyr and this is just the beginning!